MoonLake Immunotherapeutics MLTX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Long-Lived Assets by Geography | ||||||
| Portugal | $4.21M-6.2% | $4.48M-5.1% | $4.72M-1.1% | $4.77M+6.3% | $4.49M+7.5% | |
| Switzerland | $2.07M+20.2% | $1.72M-14.3% | $2.01M-12.4% | $2.3M-10.9% | $2.58M-9.8% | |
| United Kingdom | $3.7M-21.0% | $4.69M-17.2% | $5.66M-14.5% | $6.62M-12.6% | $7.57M-11.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does MoonLake Immunotherapeutics break its business down?
- MoonLake Immunotherapeutics (MLTX) reports long-lived assets by geography across 3 parts — Portugal, Switzerland and United Kingdom. Each is extracted from the segment footnotes and tracked over time.
- Where does MoonLake Immunotherapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in MoonLake Immunotherapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.